autologous anti-EGFR CAR-transduced CXCR 5-modified T lymphocytes

{
  "id": "MLC-T-ONC-011423",
  "term": "autologous anti-EGFR CAR-transduced CXCR 5-modified T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous, C-X-C chemokine receptor type 5 (CXCR 5)-modified T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-EGFR CAR-transduced CXCR 5-modified T lymphocytes target and bind to EGFR-expressing tumor cells, thereby inducing selective toxicity in EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. CXCR5, and its ligand C-X-C motif chemokine 13 (CXCL13), are associated with a variety of tumors. CXCR5-CXCL13 interactions may be involved in the regulation of lymphocyte infiltration within the tumor microenvironment (TME).",
  "synonyms": [
    "autologous anti-EGFR CAR-transduced CXCR 5-modified T cells",
    "autologous CXCR5-modified anti-EGFR CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-egfr-car-transduced-cxcr-5-modified-t-lymphocytes/"
}